# Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects

> **NCT02468908** · PHASE1 · COMPLETED · sponsor: **Savara Inc.** · enrollment: 42 (actual)

## Conditions studied

- Pulmonary Alveolar Proteinosis
- Bronchiectasis
- Cystic Fibrosis
- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** Molgramostim
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02468908
- **Lead sponsor:** Savara Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02468908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02468908, "Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02468908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*